Modulators Of Dnm2 Expression Freier; Susan M. ; et al. [Ionis Pharmaceuticals, Inc.]

U.S. Patent Application 20190241896 for Modulators Of Dnm2 Expression

A Combination of Native LC-MS Approaches for the Comprehensive Characterization of the Antibody-Drug Conjugate Trastuzumab Deruxtecan

Brett P. Monia's research works Ionis Pharmaceuticals, Carlsbad and other places

Molecular probes for the human adenosine receptors

JCI Insight - Physiological impact and disease reversion for the severe form of centronuclear myopathy linked to dynamin

EPIX: Multiple Ongoing Studies of EPI-7386…

Isomer Separation with Vocus Ion Mobility Spectrometry - TOFWERK

Modulators Of Dnm2 Expression Freier; Susan M. ; et al. [Ionis Pharmaceuticals, Inc.]

A DNM2 Centronuclear Myopathy Mutation Reveals a Link between Recycling Endosome Scission and Autophagy - ScienceDirect

IJMS, Free Full-Text

WO1992005186A1 - Modified internucleoside linkages - Google Patents

Clemmer Group: Indiana University Bloomington

WO2019089692A1 - MODULATORS OF ENaC EXPRESSION - Google Patents

EP0348458B1 - Dna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes